HH-003 + tenofovir alafenamide

HH-003 + tenofovir alafenamide is a **combination therapy** consisting of HH-003, a first-in-class human monoclonal antibody targeting the pre-S1 domain of the HBV large envelope protein, and tenofovir alafenamide, a nucleotide reverse transcriptase inhibitor (NRTI) prodrug. HH-003 directly blocks hepatitis B virus (HBV) and hepatitis D virus (HDV) entry into hepatocytes by inhibiting the preS1 domain from engaging the NTCP (sodium taurocholate co-transporting polypeptide) receptor, and clears free virions and infected hepatocytes via Fc-dependent immunological effector functions. Tenofovir alafenamide is an oral small molecule prodrug developed by Gilead Sciences, converted intracellularly to tenofovir diphosphate, which inhibits viral reverse transcriptase and DNA replication. Their combined use is being investigated as a promising therapy to achieve a functional cure in chronic hepatitis B, including cases co-infected with HDV, leveraging synergistic antiviral mechanisms while improving safety and efficacy profiles over existing therapies[1][2][4][6].

Other names

HH-003 + tenofovir alafenamide